{
    "nct_id": "NCT04067115",
    "official_title": "SARC037: a Phase I/II Study to Evaluate the Safety of Trabectedin Administered As a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging",
    "inclusion_criteria": "* diagnosis of relapsed and refractory Ewing sarcoma with EWS-FLI1 fusion type for which there is no known therapy proving to prolong survival\n* measurable disease\n* ECOG Performance Status of 0-2 or Lansky of 50\n* adequate organ function\n* written, voluntary consent\n* willing to undergo tumor biopsy\n* negative hepatitis infection\nHealthy volunteers allowed\nMust have minimum age of 6 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* prior therapy with trabectedin or lurbinectedin\n* known history of hypersensitivity to irinotecan or topotecan or their excipients.\n* known brain metastases\n* known bleeding diathesis\n* pregnant or breastfeeding\n* currently receiving other investigational drugs or anticancer agents\n* clinically significant unrelated illness or uncontrolled infection\n* unable to comply with the safety monitoring requirements",
    "miscellaneous_criteria": ""
}